

Subject:	Entyvio (vedolizumab)		
Document #:	ING-CC-0071	Publish Date:	12/20/2021
Status:	Revised	Last Review Date:	11/19/2021

Table of Contents

Overview	Coding	References
Clinical criteria	Document history	

Overview

This document addresses the use of Entyvio (vedolizumab), an integrin receptor antagonist which binds specifically to the $\alpha 4\beta 7$ integrin and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal tissue. Entyvio (vedolizumab) is approved for the treatment of Crohn’s disease and ulcerative colitis.

Crohn’s Disease: According to the American Gastrointestinal Association clinical practice guidelines, evidence supports the use of methotrexate, corticosteroids, tumor necrosis factor inhibitors (TNFi) +/- immunomodulator, ustekinumab, or vedolizumab for induction of remission. Among the biologics, infliximab, adalimumab, ustekinumab, or vedolizumab are recommended or suggested over certolizumab for induction of remission. Evidence supports biologic agents, thiopurines, and methotrexate for maintenance of remission. Ustekinumab and vedolizumab are options for individuals with primary nonresponse to initial treatment with TNFi. Adalimumab, ustekinumab, or vedolizumab may be used in cases where an individual previously responded to infliximab and then lost response (secondary nonresponse).

Ulcerative Colitis: For those with moderately to severely active disease, the American College of Gastroenterology (ACG) guidelines strongly recommend induction of remission using oral budesonide MMX, oral systemic corticosteroids, TNFi, tofacitinib or vedolizumab (moderate to high quality evidence). The American Gastroenterological Association (AGA) guidelines define moderate to severe UC as those who are dependent on or refractory to corticosteroids, have severe endoscopic disease activity, or are at high risk of colectomy. AGA strongly recommends biologics (TNFi, vedolizumab, or ustekinumab) or tofacitinib over no treatment in induction and maintenance of remission (moderate quality of evidence). For biologic-naïve individuals, Infliximab or vedolizumab are conditionally recommended over adalimumab for induction of remission (moderate quality evidence).

Pediatric Use: Two publications (Conrad 2016, Singh 2016) describe the safety and efficacy of Entyvio (vedolizumab) in pediatric individuals with Crohn’s disease or ulcerative colitis who had failed prior treatment with conventional therapy or one or more TNFi. Based on the available peer-reviewed literature and views of relevant medical specialists practicing in pediatrics and pediatric gastroenterology, the use of vedolizumab to induce or maintain remission may be considered a treatment option in a subset of the pediatric population 6 years of age or older with Crohn’s disease or ulcerative colitis who are refractory to treatment with conventional drug therapy or TNFi.

Clinical Criteria

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Entyvio (vedolizumab)

Initial requests for Entyvio (vedolizumab) may be approved for the following:

- I. Crohn’s disease (CD) when the following criteria are met:
 - A. Individual is 6 years of age or older (Conrad 2016, Singh 2016) with moderate to severe CD; **AND**

- B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy (such as systemic corticosteroids or immunosuppressants);

OR

- II. Ulcerative colitis (UC) when the following criteria are met:
 - A. Individual is 6 years of age or older (Conrad 2016, Singh 2016) with moderate to severe UC; **AND**
 - B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy (such as 5-Aminosalicylic acid products, systemic corticosteroids, or immunosuppressants).

Continuation requests for Entyvio (vedolizumab) may be approved if the following criterion is met:

- I. There is confirmation of clinically significant improvement or stabilization in clinical signs and symptoms of the disease.

Requests for Entyvio (vedolizumab) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. In combination with apremilast, JAK inhibitors, ozanimod, other biologic drugs (such as TNF antagonists, natalizumab or ustekinumab); **OR**
- III. Active, serious infection or a history of recurrent infections; **OR**
- IV. New or worsening neurological signs or symptoms of John Cunningham virus (JCV) infection or risk of progressive multifocal leukoencephalopathy (PML).

Quantity Limits

Entyvio (vedolizumab) Quantity Limit

Drug	Limit
Entyvio 300 mg/vial*	1 vial per 56 days (8 weeks)
Override Criteria	
*Initiation of therapy for Crohn's Disease (CD) or Ulcerative Colitis (UC): May approve up to 2 (two) additional single-use vials (300 mg/vial) in the first 6 weeks (42 days) of treatment.	

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

J3380 Injection, vedolizumab, 1 mg [Entyvio]

ICD-10 Diagnosis

K50.00-K50.919 Crohn's disease (regional enteritis)

K51.00-K51.919 Ulcerative colitis

Document History

Revised: 11/19/2021

Document History:

- 11/19/2021 – Annual Review: Update prior trial requirements to remove TNF antagonists to align with other agents; update exclusion list for concomitant therapy with ozanimod. Coding reviewed: No changes.
- 11/20/2020 – Annual Review: Add continuation of use section; remove 5-ASA products as example of conventional therapy for Crohn's disease; add additional examples of combination use for clarity. Coding Reviewed: No changes.
- 09/23/2019 - Administrative update to add drug specific quantity limit.
- 11/16/2018 – Annual Review: Initial P&T review of Entyvio Clinical Guideline. Update clinical criteria to delete “active” disease wording. Update criteria to delete requirement agent is being used “to reduce signs and symptoms, maintain clinical response” etc. Wording and formatting changes to criteria for consistency. HCPCS and ICD-10 Coding Review: No changes.

References

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 30, 2021.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. Feuerstein JD, Ho EY, Shmidt E et al. American Gastroenterological Association Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology* 2021; 160:2496-2508.
6. Feuerstein JD, Issacs KL, Schneider Y, et al. American Gastroenterological Association Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology* 2020; 158:1450-1461.
7. Lichtenstein GR, Loftus EV, Isaacs KL et al. 2018 American College of Gastroenterology Guideline for the management of Crohn's disease in adults. *Am J Gastroenterol* 2018; 113:481–517.
8. Rubin DT, Ananthakrishnan AN, Siegel CA et al. American College of Gastroenterology Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol* 2019; 114:384-413.
9. Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. *Inflamm Bowel Dis*. 2016; 22(10):2425-2431.
10. Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. *Inflamm Bowel Dis*. 2016; 22(9):2121-2126.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association